Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.67B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$1.58B |
| 3 |
TE Connectivity
TEL
|
+$948M |
| 4 |
Tesla
TSLA
|
+$910M |
| 5 |
Boeing
BA
|
+$829M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Dynamics
GD
|
+$1.7B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Visa
V
|
+$1.5B |
| 4 |
Morgan Stanley
MS
|
+$1.27B |
| 5 |
Exelon
EXC
|
+$1.19B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.17% |
| 2 | Healthcare | 17.88% |
| 3 | Financials | 14.68% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Beam Therapeutics
BEAM
$2.92B
| $882K | ﹤0.01% |
35,569
-3,427
| -9% | -$87.5K |
|
1652
AnaptysBio
ANAB
$1.63B
| $880K | ﹤0.01% |
66,467
+528
| +0.8% | +$12.8K |
|
1653
Iovance Biotherapeutics
IOVA
$1.95B
| $869K | ﹤0.01% |
117,426
-12,056
| -9% | -$112K |
|
1654
Ameriprise Financial
AMP
$48.9B
| $866K | ﹤0.01% |
1,627
+261
| +19% | +$139K |
|
|
THRD
1655
DELISTED
Third Harmonic Bio
THRD
| $858K | ﹤0.01% |
83,392
+6,022
| +8% | +$75K |
|
1656
Supernus Pharmaceuticals
SUPN
$2.51B
| $850K | ﹤0.01% |
23,500
-2,826
| -11% | -$99.5K |
|
1657
Viatris
VTRS
$20.6B
| $848K | ﹤0.01% |
68,148
+6,274
| +10% | +$77.1K |
|
|
ITOS
1658
DELISTED
iTeos Therapeutics
ITOS
| $847K | ﹤0.01% |
110,332
+4,563
| +4% | +$39.2K |
|
1659
Agios Pharmaceuticals
AGIO
$1.89B
| $838K | ﹤0.01% |
25,489
-3,959
| -13% | -$186K |
|
1660
Afya
AFYA
$1.27B
| $829K | ﹤0.01% |
+52,203
| New | +$860K |
|
1661
Weatherford International
WFRD
$6.41B
| $826K | ﹤0.01% |
11,537
-143,678
| -93% | -$11.8M |
|
|
MRSN
1662
DELISTED
Mersana Therapeutics
MRSN
| $824K | ﹤0.01% |
23,046
-1,686
| -7% | -$87.2K |
|
1663
Celcuity
CELC
$4.51B
| $822K | ﹤0.01% |
62,776
+11,165
| +22% | +$158K |
|
1664
Ligand Pharmaceuticals
LGND
$6.03B
| $815K | ﹤0.01% |
7,603
-1,085
| -12% | -$123K |
|
|
LENZ
1665
LENZ Therapeutics
LENZ
$158M
| $815K | ﹤0.01% |
28,216
+3,595
| +15% | +$110K |
|
1666
Organogenesis Holdings
ORGO
$305M
| $814K | ﹤0.01% |
254,282
+12,634
| +5% | +$42.4K |
|
1667
Fulcrum Therapeutics
FULC
$290M
| $809K | ﹤0.01% |
172,158
-4,003
| -2% | -$14.8K |
|
1668
MasterBrand
MBC
$1.21B
| $805K | ﹤0.01% |
55,113
| – | – |
|
1669
Baxter International
BAX
$14.7B
| $804K | ﹤0.01% |
27,558
-709
| -3% | -$23.9K |
|
1670
Equity Lifestyle Properties
ELS
$12.6B
| $803K | ﹤0.01% |
12,054
+673
| +6% | +$46.7K |
|
1671
Arq
ARQ
$88.9M
| $793K | ﹤0.01% |
+104,745
| New | +$689K |
|
1672
Amylyx Pharmaceuticals
AMLX
$2.43B
| $793K | ﹤0.01% |
+209,708
| New | +$987K |
|
1673
iShares Russell 1000 Value ETF
IWD
$83.4B
| $788K | ﹤0.01% |
4,254
+44
| +1% | +$8.44K |
|
1674
Lumentum
LITE
$66.1B
| $784K | ﹤0.01% |
+9,337
| New | +$728K |
|
1675
Recursion Pharmaceuticals
RXRX
$1.76B
| $777K | ﹤0.01% |
114,945
+9,927
| +9% | +$66.7K |
|
Similar funds
Wellington Management Group's Q4 2024 Portfolio in Review
As of Q4 2024, Wellington Management Group held 2,066 positions worth $546B, down 4.3% from $571B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Wellington Management Group withdrew a net $25.7B in Q4 2024, closing 139 positions and reducing 894 holdings. Its most notable exit was Lineage Inc, an estimated $266M position sold in full.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Wellington Management Group opened a new position in TE Connectivity worth $910M.
- Wellington Management Group's largest Q4 2024 buy was TE Connectivity: 6,362,160 shares worth $910M.
- Wellington Management Group added most to Eli Lilly in Q4 2024, an estimated $1.67B increase.
- Wellington Management Group's biggest Q4 2024 reduction was General Dynamics, cutting an estimated $1.7B.
- Wellington Management Group fully exited Lineage Inc in Q4 2024, selling an estimated $266M.
- Wellington Management Group's ten largest holdings make up 25% of its $546B portfolio in Q4 2024.
- Wellington Management Group opened 161 new positions and closed 139 in Q4 2024.
- Wellington Management Group's portfolio value fell 4.3% quarter-over-quarter to $546B.
Based on Wellington Management Group's 13F filing for Q4 2024, filed 12 Feb 2025.